{"Title": "Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial", "Year": 2019, "Source": "Nat. Med.", "Volume": "25", "Issue": 11, "Art.No": null, "PageStart": 1706, "PageEnd": 1714, "CitedBy": 70, "DOI": "10.1038/s41591-019-0628-7", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85074774717&origin=inward", "Abstract": "\u00a9 2019, The Author(s), under exclusive licence to Springer Nature America, Inc.Antibodies targeting PD-1 or its ligand 1 PD-L1 such as atezolizumab, have great efficacy in a proportion of metastatic urothelial cancers1,2. Biomarkers may facilitate identification of these responding tumors3. Neoadjuvant use of these agents is associated with pathological complete response in a spectrum of tumors, including urothelial cancer4\u20137. Sequential tissue sampling from these studies allowed for detailed on-treatment biomarker analysis. Here, we present a single-arm phase 2 study, investigating two cycles of atezolizumab before cystectomy in 95 patients with muscle-invasive urothelial cancer (ClinicalTrials.gov identifier: NCT02662309). Pathological complete response was the primary endpoint. Secondary endpoints focused on safety, relapse-free survival and biomarker analysis. The pathological complete response rate was 31% (95% confidence interval: 21\u201341%), achieving the primary efficacy endpoint. Baseline biomarkers showed that the presence of preexisting activated T cells was more prominent than expected and correlated with outcome. Other established biomarkers, such as tumor mutational burden, did not predict outcome, differentiating this from the metastatic setting. Dynamic changes to gene expression signatures and protein biomarkers occurred with therapy, whereas changes in DNA alterations with treatment were uncommon. Responding tumors showed predominant expression of genes related to tissue repair after treatment, making tumor biomarker interpretation challenging in this group. Stromal factors such as transforming growth factor-\u03b2 and fibroblast activation protein were linked to resistance, as was high expression of cell cycle gene signatures after treatment.", "AuthorKeywords": null, "IndexKeywords": ["Aged", "Antibodies, Monoclonal, Humanized", "Biomarkers, Tumor", "Carcinoma, Transitional Cell", "Disease-Free Survival", "DNA Repair", "Female", "Gene Expression Regulation, Neoplastic", "Humans", "Male", "Middle Aged", "Neoadjuvant Therapy", "Neoplasm Invasiveness", "Transcriptome", "Transforming Growth Factor beta", "Urologic Neoplasms", "Urothelium"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 2, "EID": "2-s2.0-85074774717", "SubjectAreas": [["Biochemistry, Genetics and Molecular Biology (all)", "BIOC", "1300"]], "AuthorData": {"34572458000": {"Name": "Powles T.", "AuthorID": "34572458000", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London"}, "56324526500": {"Name": "Szabados B.", "AuthorID": "56324526500", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London"}, "57210840427": {"Name": "Prendergast A.", "AuthorID": "57210840427", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London"}, "56845484000": {"Name": "Mousa K.", "AuthorID": "56845484000", "AffiliationID": "60021435, 60022109", "AffiliationName": "Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London"}, "7005476113": {"Name": "Kockx M.", "AuthorID": "7005476113", "AffiliationID": "121601261", "AffiliationName": "HistogeneX N.V."}, "55411933300": {"Name": "van Dam P.J.", "AuthorID": "55411933300", "AffiliationID": "121601261", "AffiliationName": "HistogeneX N.V."}, "57211663789": {"Name": "Stanoeva D.", "AuthorID": "57211663789", "AffiliationID": "121601261", "AffiliationName": "HistogeneX N.V."}, "57188961610": {"Name": "Daelemans S.", "AuthorID": "57188961610", "AffiliationID": "60012937", "AffiliationName": "Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp"}, "55780021900": {"Name": "Rodriguez-Vida A.", "AuthorID": "55780021900", "AffiliationID": "60023506", "AffiliationName": "Department of Medical Oncology, Hospital del Mar"}, "7005607034": {"Name": "Duran I.", "AuthorID": "7005607034", "AffiliationID": "60033267, 60033284, 60006754, 60103764", "AffiliationName": "Instituto de Biomedicina de Sevilla, IBiS, Hospital Universitario Virgen del Rocio, CSIC and Universidad de Sevilla"}, "11739253300": {"Name": "Crabb S.J.", "AuthorID": "11739253300", "AffiliationID": "60025225", "AffiliationName": "Southampton Experimental Cancer Medicine Centre, University of Southampton"}, "7005587639": {"Name": "Van Der Heijden M.S.", "AuthorID": "7005587639", "AffiliationID": "60015205", "AffiliationName": "Department of Medical Oncology, The Netherlands Cancer Institute"}, "57211661808": {"Name": "Pous A.F.", "AuthorID": "57211661808", "AffiliationID": "60028462, 60015633", "AffiliationName": "Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B.ARGO)-IGTP, Hospital Universitari Germans Trias i Pujol"}, "7003514831": {"Name": "Gravis G.", "AuthorID": "7003514831", "AffiliationID": "60028690", "AffiliationName": "Institut Paoli-Calmettes"}, "37118635600": {"Name": "Herranz U.A.", "AuthorID": "37118635600", "AffiliationID": "60002983", "AffiliationName": "Department of Medical Oncology, Hospital Clinico Universitario de Santiago"}, "8922675100": {"Name": "Protheroe A.", "AuthorID": "8922675100", "AffiliationID": "60021328", "AffiliationName": "Department of Medical Oncology, Churchill Hospital"}, "7006184228": {"Name": "Ravaud A.", "AuthorID": "7006184228", "AffiliationID": "60102125, 60026122, 60021564", "AffiliationName": "Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux\u2013CHU Bordeaux"}, "55314917000": {"Name": "Maillet D.", "AuthorID": "55314917000", "AffiliationID": "60001780", "AffiliationName": "Department of Medical Oncology, Hospital Lyon Sud"}, "57023087400": {"Name": "Mendez M.J.", "AuthorID": "57023087400", "AffiliationID": "60031142", "AffiliationName": "Department of Medical Oncology, Reina Sofia University Hospital"}, "35605048600": {"Name": "Suarez C.", "AuthorID": "35605048600", "AffiliationID": "60012486, 60023020", "AffiliationName": "Vall d\u2019Hebron Institute of Oncology, Vall d\u2019Hebron University Hospital, Universitat Autonoma de Barcelona"}, "23489393000": {"Name": "Linch M.", "AuthorID": "23489393000", "AffiliationID": "60024544", "AffiliationName": "Department of Medical Oncology, University College London Hospital"}, "6602100395": {"Name": "Mariathasan S.", "AuthorID": "6602100395", "AffiliationID": "60026209", "AffiliationName": "Genentech"}, "57211661797": {"Name": "Tea J.S.", "AuthorID": "57211661797", "AffiliationID": "60026209", "AffiliationName": "Genentech"}, "26326738900": {"Name": "Banchereau R.", "AuthorID": "26326738900", "AffiliationID": "60026209", "AffiliationName": "Genentech"}, "55901642500": {"Name": "Castellano D.", "AuthorID": "55901642500", "AffiliationID": "60004024", "AffiliationName": "Department of Medical Oncology, Hospital 12 de Octubre"}}}